| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Jae-Hyun Park CEO | KRX SM Exchange | KR7128940004 ISIN |
| KR Country | 2,400 Employees | - Last Dividend | 27 Dec 2023 Last Split | - IPO Date |
Hanmi Pharm. Co., Ltd. is an established biopharmaceutical entity dedicated to the development, production, and global distribution of pharmaceutical products. Since its inception in 1973, the company has been headquartered in Hwaseong-si, South Korea. With a solid footprint in key markets including South Korea, China, Japan, the United States, and other international territories, Hanmi Pharm has committed itself to addressing some of the most pressing health challenges. The company stands out for its concentrated efforts in tackling diseases that pose significant unmet medical demands, focusing on areas such as obesity, metabolism, oncology, and rare diseases. This strategic focus underscores Hanmi Pharm’s dedication to pioneering in territories where patient needs are yet to be fully met, leveraging both innovative research and development capabilities alongside a robust manufacturing infrastructure to deliver solutions that aim to improve patient outcomes across the globe.
Hanmi Pharm. Co., Ltd. specializes in a range of products and services designed to confront unmet medical needs, particularly in the fields of obesity, metabolism, oncology, and rare diseases. Below are key areas of focus: